Emerging Med - Secondary
8:30 AM - 6:00 PM EST (M-F)
Find trials
that match your profile.


This website is certified by Health On the Net Foundation. Click to verify.
About EmergingMed
Our Mission
Our Privacy Policy
Our Patented Clinical Trial Matching Service
Our History
Our Management
Our Medical Advisory Board
Our Collaborations with Patient Advocacy Organizations
  How We Get Paid
Letter from the CEO



About EmergingMed   Top
EmergingMed® is the leading innovator in clinical trial enrollment optimization. The Company provides services for patients that raise awareness and facilitate access to clinical trials. These patient-focused services are part of the broader solution EmergingMed hosts for clinical trial sponsors and investigators to manage the complexities of patient identification, recruitment and retention.. The company's broader vision is to accelerate the discovery of new and better treatments for people with serious and life threatening medical conditions.


Our Mission   Top
EmergingMed's mission is to accelerate the discovery of new and better treatments for people with serious and life threatening medical conditions. Since 2000, the Company’s focus has been the creation of patient-centric tools and services that quickly and accurately connect patients and health care providers to clinical trials testing new therapies in development. EmergingMed is committed to getting the right information to the right person at the right time—always ensuring that information is presented in context and readily actionable.


Our Privacy Policy   Top
Our commitment to privacy and security is uncompromising and guides every decision we make. We will never sell or share your personal information. All information submitted to EmergingMed is password protected, confidential and secure. Please read our Privacy Policy for details.


Our Patented Clinical Trial Matching Service   Top
EmergingMed received a patent on its System and Method for Matching Patients to Clinical Trials (US Patent No. 7,711,580 B2) in May of 2010. This matching system shortens the clinical trial search process from weeks to minutes, helping users identify clinical trials with eligibility criteria that match a patient’s specific diagnosis, stage, symptoms, and treatment history.


Our History   Top
EmergingMed was founded in January 2000 after months of interviews with patients, advocates, caregivers and researchers who helped us understand the barriers, misperceptions, and logistical challenges associated with finding relevant clinical trials and making informed treatment decisions. The EmergingMed.com website and Clinical Trial Navigation Service launched in October 2000. As of November 2014, we have facilitated clinical trial searches for nearly 200,000 cancer patients and 100,000 patients with other serious and life threatening conditions.


Our Management   Top
EmergingMed's management team has proven that it is adept at innovating as well as scaling solutions to help bring new therapies to market while empowering patients to make more informed treatment decisions.

Courtney Hudson   Courtney Hudson, CEO and co-Founder
Courtney co-founded EmergingMed in January of 2000 after spending three years as a health services research analyst and institutional sales representative for CIBC Oppenheimer in New York City. Prior to joining the boutique investment firm, Courtney worked to launch three consecutive Medicaid-focused HMO start-ups on the east coast. She was responsible for early stage business development, information systems solutions, and/or quality management programs. In the third privately funded endeavor, she managed two new state insurance application filings.

Her interest in the creation of managed care organizations in the 1990's stemmed directly from her commitment to improving access to care for vulnerable populations. Between 1987 and 1992, Courtney worked with state and academic initiatives dedicated to improving clinical outcomes for low-income pregnant women and the chronically mentally ill population in Washington State. The success of these programs hinged on implementing patient-focused solutions and coordinated information sharing among local health and social service providers.

The creation of EmergingMed's patented Clinical Trial Navigation Services reflects Courtney's commitment to creating systemic solutions to that coordinate access to care and empower patients and health care providers with unbiased information to make more informed decisions. Read the Letter from the CEO to learn how she became committed to improving patients' access to clinical trials.
Courtney holds a B.S. in neurobiology from Yale University and an M.B.A. from the University of Washington in Seattle.
Robert Rutigliano, PhD, Director, Medical Information
Robert is a research scientist with 10 years of laboratory experience in Molecular Genetics and Medical Microbiology. Through a National Science Foundation training fellowship under the guidance of Dr. Dafna Bar-Sagi, Robert's research focused on signal transduction and cellular imaging of living cells in oncology. Robert has successfully parlayed his experience as a bench scientist into the role of incomparable educator of and advocate for patients as targeted therapies, molecular diagnostics, and gene expression profiling have become the centerpiece of cancer research and modern medicine.

Robert earned a B.A. in History from James Madison University in Harrisonburg, VA, and a Ph.D. in Molecular Genetics and Medical Microbiology from Stony Brook University in Stony Brook, NY.

Our Medical Advisory Board   Top
EmergingMed’s advisors provide invaluable guidance to EmergingMed’s staff as they operationalize processes to bring unbiased, comprehensive clinical trial information to the public and place new therapeutic strategies and diagnostics in context.

The following is a list of our oncology advisory board members:

  Daniel Von Hoff, M.D., F.A.C.P., is currently Professor of Medicine, Pathology, Molecular and Cellular Biology, Director of the Arizona Health Sciences Center's Cancer Therapeutics Program, Executive Vice President, Translational Genomics Research Institute (TGen), Director, TGen's Translational Drug Development Division and Head, Pancreatic Cancer Research Program. He is also Chief Scientific Officer for US Oncology.

Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies.

Dr. Von Hoff's laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient. He and his laboratory are now concentrating on discovery of new targets in pancreatic cancer. Dr. Von Hoff has published more than 515 papers, 127 book chapters, and more than 850 abstracts. Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in June 2004 - March 2010. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEXTM Oncology, Inc. (recently acquired by Genzyme). He is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
  David S. Alberts, M.D., is currently Regents Professor of Medicine, Pharmacology, Nutritional Science, and Public Health at the University of Arizona College of Medicine, and Director of the Arizona Cancer Center. He has had a strong career focus on translational cancer prevention and treatment research. The emphasis of his laboratory-based and clinical research has been on the chemoprevention and treatment of such pervasive and potentially deadly diseases as cancers of the breast, colon, ovary, and skin. Clinically, Dr. Alberts pioneered new treatments for advanced ovarian cancers, including in vitro tumor cell chemosensitivity testing for personalized medicine strategies, intraperitoneal chemotherapy, and maintenance chemotherapy. Presently, Dr. Alberts helps to coordinate Phase I and II and pharmacokinetic drug studies at the Arizona Cancer Center for molecularly-targeted chemopreventive agents and anticancer drugs. His laboratory research is concentrated on the evaluation of new surrogate endpoint biomarkers for cancer prevention trials with a special focus on precursor lesions for bladder, breast, colon, cervical, endometrial, ovarian, prostate, and skin cancers, using quantitative histopathology (i.e. karyometric) approaches. Dr. Alberts has authored or co-authored over 499 peer reviewed publications, more than 100 book chapters and 60 invited articles, and has served as Editor and Co-Editor of six books (e.g. Fundamentals of Cancer Prevention, Second Edition, Springer Verlag, 2009 and Intraperitoneal Therapy for Ovarian Cancer, Springer Verlag, 2010). He has served on the editorial boards of several peer-reviewed scientific journals including Associate Editor for Cancer Research from 1989-2002. Between 2002 and 2008, he acted as the Co-Editor-in-Chief of Cancer Epidemiology, Biomarkers & Prevention, the leading cancer public health research journal worldwide.

Dr. Alberts received his MD in 1966 from University of Virginia School of Medicine. He conducted his internship at the University of Wisconsin, before becoming a Clinical Associate in medical oncology at the National Cancer Institute's Baltimore Cancer Research Center. Dr. Alberts conducted his internal medicine residency at the University of Minnesota and then served on the faculty of the University of California, San Francisco, for five years and obtained Board certification in Medicine and Medical Oncology in 1973. He joined the University of Arizona College of Medicine in 1975 as an Assistant Professor, where he has served for nearly 35 years.
  George D. Demetri, M.D., is director of the Center for Sarcoma and Bone Oncology at DFCI, director of the Ludwig Center at Dana-Farber/Harvard Cancer Center, and executive director for Clinical and Translational Research at the Ludwig Institute for Cancer Research. His primary area of research is molecular targeted agents and signal transduction inhibitors. Dr. Demetri's group is currently focused on translating research on the basic biology of sarcomas into new therapeutics directed at novel targets.

Dr. Demetri received his medical degree from Stanford University School of Medicine. He completed his residency in internal medicine at University of Washington Hospitals and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute. He is board-certified in medical oncology and internal medicine.

Dr. Demetri received the Focused Giving Program Award, Johnson and Johnson Foundation in 1993, the Emil J. Freireich Award in Clinical Cancer Research in 2002 and the Claire W. and Richard P. Morse Research Award in 2005.
  Robert A. Figlin, M.D., F.A.C.P., is the Arthur and Rosalie Kaplan Professor of Medical Oncology and chair of the Department of Medical Oncology & Therapeutics Research at City of Hope.

A nationally recognized leader in genitourinary and thoracic oncology, Dr. Figlin focuses his research on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at City of Hope, which aims to understand the biology of kidney cancer and translate that knowledge into new treatments. His leadership in developing novel anticancer drugs that avoid the toxicity associated with standard treatments furthers City of Hope's tradition of compassionate patient care. He previously served as the co-principal investigator of the University of California, Los Angeles (UCLA) Lung Cancer Specialized Program of Research Excellence (SPORE), which he brought to City of Hope as part of the Southern California Lung Cancer Consortium.

Prior to joining City of Hope, Dr. Figlin served as the Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology and professor of medicine and urology in the divisions of Hematology/Oncology and Urologic Oncology at the David Geffen School of Medicine at UCLA. Dr. Figlin joined the UCLA faculty in 1982 as assistant professor of medicine in the Division of Hematology/Oncology and was appointed co-director of the Jonsson Comprehensive Cancer Center's oncology program in 1993. He also held the post of medical director of the Thoracic and Genitourinary Oncology Program in the departments of Medicine, Surgery and Urology, and served as program director of Solid Tumor Development Therapeutics within the cancer center.

Dr. Figlin serves as editor for the Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, the Journal of Clinical Oncology and the Journal of Urology, among others. Dr. Figlin received his medical degree from the Medical College of Pennsylvania. He completed his residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology the David Geffen School of Medicine. He is board-certified in medical oncology and internal medicine.
  Henry S. Friedman, M.D.,is an internationally recognized neuro-oncologist with a career-long interest in the treatment of children and adults with brain and spinal cord tumors. As Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, he brings a unique team of specialists to the battle against brain tumors. The Brain Tumor Program at Duke was founded in 1937 and has the distinction of being one of the first in the United States; it also has the distinction of being one of the largest and most successful programs of its kind in the country. Focused specifically in the treatment and cure of brain and spinal tumors in children and adults, The Preston Robert Tisch Brain Tumor Center at Duke combines the resources of a leading research organization with a commitment to the best in patient care, having treated more than 6,000 patients at the center in the last 10 years. Dr. Friedman additionally holds appointments as Professor of Pediatrics, Associate Professor of Surgery and Medicine, and Assistant Professor of Pathology. He has written hundreds of articles on both the clinical and laboratory investigation of these neoplasms.

  Gabriel N. Hortobagyi, M.D., F.A.C.P., is Professor of Medicine, Chairman of the Department of Breast Medical Oncology and Nellie B. Connally Chair in Breast Cancer at the University of Texas MD Anderson Cancer Center. He is also the Director of the Breast Cancer Research Program at the same institution. Dr. Hortobagyi has over 400 full-length publications in peer-reviewed journals; more than 300 invited papers; and over 100 book chapters to his credit.

He is recipient of the 1997 Brinker International Award, the 1999 Vermeille Medal of the City of Paris, France, and was named Chevalier of l'Ordre de la Legion d'Honneur de France in 2001. Dr. Hortobagyi received the Glen Robbins Award in Breast Cancer Research from the New York Cancer Society and the Metropolitan Breast Cancer Group in April 2003, the Bristol-Myers Squibb 2003 Horizon Scientific Award; in 2004 Dr. Hortobagyi was the Jeffrey A. Gottlieb Memorial Award recipient, and was honored as the first recipient of the Umberto Veronesi Award for the Future Fight Against Breast Cancer.

His professional society activities include membership in the American Society of Clinical Oncology, where he has served on various task forces, chaired committees, served on the Board of Directors, and in 2005 was elected President for the term 2006-2007. He chairs the Data and Safety Monitoring Committee of the National Surgical Adjuvant Breast and Bowel Project; and served as President of the International Society of Senology. He served as a member of the U.S. National Committee for the International Union Against Cancer, and the National Cancer Institute's Breast Cancer Progress Review Group. Dr. Hortobagyi is on the Medical Advisory Board of The Breast Cancer Research Foundation, chairs the Steering Committee of the Breast Health Global Initiative and the Health Advisory Board of the Susan G. Komen Breast Cancer Foundation, and was a member of the Integration Panel of the Breast Cancer Research Program of the Department of Defense.

  W. Gillies McKenna, M.D., Ph.D., is Director of the Gray Institute for Radiation Oncology and Biology at the University of Oxford which is jointly funded by Cancer Research UK, the Medical Research Council and the University of Oxford. The Institute combines the Medical Research Council's Radiation and Genome Stability Unit and Cancer Research UK's Gray Cancer Institute.

Prof. McKenna;s research links basic science studies with translational-clinical applications. His research has focused on effects of radiation on cancer cells and on mechanisms of resistance to radiation with the goal of sensitizing cells to radiation by blocking mechanisms that control cell survival. Specifically he is interested in oncogenically activated signal transduction pathways that exert a radioprotective effect on tumour cells. His group has shown that the EGFR-Ras-PI3K-PTEN-Akt pathway appears to the major radioprotective pathway active in most solid tumours and this pathway then presents targets that could be manipulated in a clinical setting to modify the radiation response. His clinical interests are the treatment of lung cancer, soft tissue sarcomas, skin cancer, head and neck cancer, and melanomas.

Professor McKenna was born in Scotland. He received a Bachelor of Science in Zoology at the University of Edinburgh in 1972. He was a member of the Medical Scientist Training Programme at the Albert Einstein College of Medicine in New York and received his M.D. and Ph.D. in 1981. His Ph.D. thesis research investigated the cleavage patterns of DNA by mammalian endonucleases. Following an Internship in Medicine at the Johns Hopkins University Hospital and a Residency in Radiation Oncology at the National Cancer Institute. Dr. McKenna moved to the Department of Radiation Oncology at the University of Pennsylvania School of Medicine where he rose to become Chairman and Henry K. Pancoast Professor of Radiation Oncology. In 2005 he moved to his present position.

He is the author of over 90 research articles and 40 editorials, reviews and chapters. He has edited a textbook on Clinical Oncology. He was the President of the Radiation Research Society and a member of the Board of Scientific Advisors for the National Cancer Institute. He was the 2005 recipient of the Association for Radiation Research Weiss Medal.
  Michael D. Prados, M.D., F.A.C.P., has over 20 years' experience at UCSF in treating and supervising the treatment of both adults and children who have brain tumors. He is co-project leader of the Adult Brain Tumor Consortium, and he is principal investigator of the Pediatric Brain Tumor Consortium site at UCSF, which is one of 7 institutions in the United States selected to participate in this NIH-funded cooperative effort to develop effective new strategies for treating children with malignant brain tumors.

Dr. Prados, both individually and in conjunction with multi-center and multidisciplinary clinical research efforts, supervises and participates in conducting extensive trials of clinical therapy for malignant brain tumors. He is the supervising preceptor training BTRC clinical fellows in conducting clinical trials and analyzing and interpreting clinical trial data. His research interest is in clinical research trials for primary brain tumors. Dr. Prados has been a principal investigator, co-investigator, or collaborating investigator in over 35 research protocols from the National Institutes of Health (NIH), UCSF, and Industry studies over the last several years, and currently is principal investigator or co-investigator of 4 active NIH grants.
  Julie Vose, M.D., is the Neumann M. and Mildred E. Harris Professorial Chair and is the current Chief of the Oncology/Hematology Division in the Department of Internal Medicine at UNMC. Dr Vose received all of her medical education and training at UNMC and has been on faculty since 1990. Dr Vose is an internationally known leading expert in the treatment of patients with lymphoma. Dr Vose has served in many national and international review panels and is actively involved in various administrative positions in various local and national organizations. Dr Vose is actively involved in various novel clinical trials and is a member of the Nebraska Lymphoma Study Group. Dr Vose is the current co-program leader of the Hematologic Malignancy Program at the UNMC Eppley Cancer Center. Dr Vose has published over 220 articles in various medical journals, most of which deals with finding optimum care and treatment for patients with lymphoma. She has served on the editorial boards of various hematology and oncology journals, and serves as an expert reviewer as well.

Our Collaborations with Patient Advocacy Organizations   Top
EmergingMed hosts privately branded Clinical Trial Navigation Services for advocacy groups who want to bring unbiased, actionable clinical trial opportunities to their constituents. EmergingMed also collaborates with patient advocates on education and outreach programs to raise awareness of clinical trials among targeted groups. These clinical trial call-to-action campaigns encourage participants to engage clinical trial matching and referral services and register to receive updates when new clinical trials become available that match a person’s specific clinical and genomic profile.


How We Get Paid   Top
EmergingMed's clinical trial matching, referral, and navigation services are provided free of charge to patients and physicians searching for clinical trials. EmergingMed receives monthly subscription fees for processing phone-based and/or web-based clinical trial inquiries on behalf of other organizations (e.g., patient advocacy groups, pharmaceutical and biotechnology companies, trial sites and research networks, and diagnostic companies). EmergingMed is never paid for referring or enrolling a patient in a trial.


Sponsorship   Top
EmergingMed is a private company owned and operated by Final Four Health Solutions, LLC, a family-owned organization dedicated to accelerating the development of new and better treatments for people with serious and life threatening conditions. EmergingMed and FFHS' are headquartered at 2605 Meridian Parkway, Suite 115, Durham, NC 27713. EmergingMed has chosen not to accept investments from trial sponsors to ensure that our services remain unbiased.


Letter from the CEO   Top
Late one Sunday evening In January 1999, my husband called me on his cell phone from a taxi. He was seriously ill and on his way to the hospital. The doctors were able to stabilize him temporarily, but they recommended additional surgery. My husband refused to undergo what would be a long, difficult operation that would require months of recovery. I was obviously upset - not only about my husband's condition, but also about his apparent unwillingness to accept the recommended treatment.

I was torn between the competing desires to respect his choices and to convince him to get treatment immediately. I began to search for treatment options, mainly through the Internet, but found the information presented too simplistic, too scientific, or too voluminous. By chance, a friend in California sent my husband an article about an alternative surgery at another hospital that had only recently been developed. This surgery was being performed only a few miles from our home in New York City, yet we had never heard about it. My husband underwent this surgery, and eleven years later is still doing fine.

EmergingMed created its clinical trial matching and referral system to quickly and accurately connect patients with appropriate clinical trial options. We added personalized education and one-on-one support with Clinical Trial Navigators to help families make sense of these options, understand the narrow timeframes for joining a clinical trial, and identify and fix barriers that might otherwise interfere with a family's ability to seriously consider enrolling in a clinical trial.

No family should ever have to ask: "Why didn't anyone tell us?"


Courtney Hudson
CEO and Founder, EmergingMed

Modified: May 2016
© 2016 EmergingMed Home  |  Contact Us  |  How Matching Works  |  Privacy Policy  |  Terms & Conditions